Intranasal interleukin-12 is a powerful adjuvant for protective mucosal immunity

Journal of Infectious Diseases

Volumn 180, Issue 4, 1999, Pages 940-949

  Arulanandam, Bernard P ^a,c   O'Toole, Margot ^b   Metzger, Dennis W ^a,c  

^a MEDICAL COLLEGE OF OHIO   (United States)

^b PFIZER INC   (United States)

^c ALBANY MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; INTERLEUKIN 10; INTERLEUKIN 12; SIALIDASE; VIRUS HEMAGGLUTININ;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOSTIMULATION; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A; INTERFERON PRODUCTION; MOUSE; PRIORITY JOURNAL; VIRUS RESISTANCE;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, VIRAL; FEMALE; GENE EXPRESSION REGULATION; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INFLUENZA VACCINES; INTERFERON TYPE II; INTERLEUKIN-10; INTERLEUKIN-12; LUNG; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEURAMINIDASE; ORTHOMYXOVIRIDAE INFECTIONS; RNA, MESSENGER; SPLEEN; TIME FACTORS;

EID: 0033401040     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/314996     Document Type: Article

References (50)

1. Staats HF, McGhee JR. Application of basic principles of mucosal immunity to vaccine development. In: Kiyono H, Ogra PL, McGhee JR, eds. Mucosal Vaccines. New York: Academic Press, 1996:17-39.
2. Van Regenmortel M. Searching for safer, more potent, better-targeted. adjuvants. ASM News 1997;63:136-9.
3. Staats HF, Jackson RJ, Marinaro M, Takahashi, I, Kiyono H, McGhee JR. Mucosal immunity to infection with implications for vaccine development. Curr Opin Immunol 1994;6:572-83.
4. Elson CO. In defence of mucosal surfaces: regulation and manipulation of the mucosal immune system. In: Paul PS, Francis DH, Benfield, DA, eds. Mechanisms in the Pathogenesis of Enteric Disease. New York: Plenum Press, 1997:373-85.
5. Graham BS, Bunton LA, Wright PF, Karzon DT. Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice. J Clin Invest 1991;88:1026-33.
6. Graham BS, Henderson GS, Tang YW, Lu X, Neuzil KM, Colley DG. Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus. J Immunol 1993;151:2032-40.
7. Kobayashi M, Fitz L, Ryan M, et al. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med 1989:170:827-45.
8. Macatonia SE, Hosken NA, Litton M, et al. Dendritic cells produce IL-12 and direct the development of Thl cells from naive CD4' T cells. J Immunol 1995;154:5071-9.
9. Trinchieri G, Scott P. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions. Res Immunol 1995;146:423-31.
10. Gately MK, Renzetti LM, Magram J, et al. The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses. Annu Rev Immunol 1998;16:495-521.
11. Buchanan JM, Vogel LA, Van Cleave VH, Metzger DW. Interleukin 12 alters the isotype-restricted antibody response of mice to hen egg white lysozyme. Int Immunol 1995;7:1519-28.
12. Metzger DW, Buchanan JM, Collins JT, et al. Enhancement of humoral immunity by interleukin-12. Ann N Y Acad Sci 1996;795:100-15.
13. Metzger DW, McNutt RM, Collins JT, Buchanan JM, Van Cleave VH, Dunnick WA. Interleukin-12 acts as an adjuvant for humoral immunity through interferon-gamma-dependent and-independent mechanisms. Eur J Immunol 1997;27:1958-65.
14. McKnight AJ, Zimmer GJ, Fogelman J, Wolf SF, Abbas AK, Effects of IL-12 on helper T cell-dependent immune responses in vivo. J Immunol 1994; 152:2172-9.
15. Morris SC, Madden KB, Adamovicz JJ, et al. Effects of IL-12 on in vivo cytokine gene expression and Ig isotype selection. J Immunol 1994;152:1047-56.
16. Germann T, Bongartz M, Dlugonska H, et al. Interleukin-12 profoundly up-regulates the synthesis of antigen-specific complement-fixing IgG2a, IgG2b and IgG3 antibody subclasses in vivo. Eur J Immunol 1995;25:823-9.
17. Wynn TA, Reynolds A, James S, et al. IL-12 enhances vaccine-induced immunity to schistosomes by augmenting both humoral and cell-mediated immune responses against the parasite. J Immunol 1996; 157:4068-78.
18. Bliss J, Van Cleave V, Murray K, et al. IL-12, as an adjuvant, promotes a T helper 1 cell, but does not suppress a T helper 2 cell recall response. J Immunol 1996;156:887-94.
19. Greenberger MJ, Kunkel SL, Strieter RM, et al. IL-12 gene therapy protects mice in lethal Klebsiella pneumonia. J Immunol 1996;157:3006-12.
20. Doherty TM, Sher A. IL-12 promotes drug-induced clearance of Mycobacterium avium infection in mice. J Immunol 1998;160:5428-35.
21. de Jong R, Altare F, Haagen IA, et al. Severe mycobacterial and Salmonella infections in interleukin-12 receptor-deficient patients. Science 1998; 280:1435-8.
22. Altare F, Durandy A, Lammas D, et al. Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency, Science 1995;280:1432-5.
23. Marinaro M, Boyaka PN, Finkelman FD, et al. Oral but not parenteral interleukin (IL)-12 redirects T helper 2 (Th2)-type responses to an oral vaccine without altering mucosal IgA responses. J Exp Med 1997; 185:415-27.
24. Okada E, Sasaki S, Ishii N, et al. Intranasal immunization of a DNA vaccine with IL-12 and granulocyte-macrophage colony-stimulating factor (GM-CSF)-expressing plasmids in liposomes induces strong mucosal and cell-mediated immune responses against HIV-1 antigens. J Immunol 1997;159:3638-47.
25. Yang Y, Trinchieri G, Wilson JM. Recombinant IL-12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung. Nat Med 1995;1:890-3.
26. Arulanandam BP, Metzger DW. Modulation of mucosal and systemic immunity by intranasal interleukin-12 delivery. Vaccine 1999;17:252-60.
27. Monteiro JM, Harvey C, Trinchieri G. Role of interleukin-12 in primary influenza virus infection. J Virol 1998;72:4825-31.
28. Buchanan RM, Arulanandam BP, Metzger DW. IL-12 enhances antibody responses to T-independent polysaccharide vaccines in the absence of T and NK cells. J Immunol 1998;161:5525-33.
29. Meyaard L, Hovenkamp E, Otto SA, Miedema E. IL-12-induced IL-10 production by human T cells as a negative feedback for IL-12-induced immune responses. J Immunol 1996;156:2776-82.
30. Daftarian PM, Kumar A, Kryworuchko M, Diaz-Mitoma F. IL-10 production is enhanced in human T cells by IL-12 and IL-6 and in monocytes by tumor necrosis factor-alpha. J Immunol 1996;157:12-20.
31. Gerosa F, Paganin C, Peritt D, et al. Interleukin-12 primes human CD4 and CD8 T cell clones for high production of both interferon-gamma and interleukin-10. J Exp Med 1996;183:2559-69.
32. Kitamura D, Roes J, Kuhn R, Rajewsky K. A B cell-deficient mouse by targeted disruption of the membrane exon of the immunoglobulin μ chain gene. Nature 1991; 350:423-6.
33. Boehm U, Klamp T, Groot M, Howard JC. Cellular responses to interferon-gamma. Annu Rev Immunol 1997;15:749-95.
34. Florentino DF, Zlotnik A, Vieira P, et al. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Thl cells. J Immunol 1991; 146:3444-51.
35. Ding L, Shevach EM. IL-10 inhibits mitogen-induced T cell proliferation by selectively inhibiting macrophage costimulatory function. J Immunol 1992;148:3133-9.
36. Lamm ME. Interaction of antigens and antibodies at mucosal surfaces. Annu Rev Microbiol 1997;51:311-40.
37. Boyaka PN, Marinaro M, Jackson RM, Menon S, Kiyono H, McGhee JR. IL-12 is an effective adjuvant for induction of mucosal immunity. J Immunol 1999;162:122-8.
38. Tang YW, Graham BS. Interleukin-12 treatment during immunization elicits a T helper cell type 1 like immune response in mice challenged with respiratory syncytial virus and improves vaccine immunogenicity. J Infect Dis 1995;172:734-8.
39. Nedrud JG, Liang XP, Hague N, Lamm ME. Combined oral/nasal immunization protects mice from Sendai virus infection. J Immunol 1987;139:3484-92.
40. Palladino G, Mozdzanowska K, Washko G, Gerhard W. Virus-neutralizing antibodies of immunoglobulin G (IgG) but not IgM or IgA isotypes can cure influenza virus pneumonia in SCID mice. J Virol 1995; 69:2075-81.
41. Epstein SL, Lo CY, Misplon JA, Bennink JR. Mechanism of protective immunity against influenza virus infection in mice without antibodies. J Immunol 1998;160:322-7.
42. Gerhard W, Mozdzanowska K, Furchner M, Washko G, Maiese K. Role of the B-cell response in recovery of mice from primary influenza virus infection. Immunol Rev 1997; 159:95-103.
43. Graham MB, Braciale TJ. Resistance to and recovery from lethal influenza virus infection in B lymphocyte-deficient mice. J Exp Med 1997; 186:2063-8.
44. Mozdzanowska K, Furchner M, Maiese K, Gerhard W. CD4' T cells are ineffective in clearing a pulmonary infection with influenza type A virus in the absence of B cells. Virology 1997; 239:217-25.
45. Topham DJ, Doherty PC. Clearance of an influenza A virus by CD4' T cells is inefficient in the absence of B cells. J Virol 1998; 72:882-5.
46. Renegar KB, Small PA Jr. Passive transfer of local immunity to influenza Virus infection by IgA antibody. J Immunol 1991; 146:1972-8.
47. Takahashi J, Marinaro M, Kiyono H, et al. Mechanisms for mucosal immunogenicity and adjuvancy of Excherichia coli labile enterotoxin. J Infect Dis 1996; 173:627-35.
48. Braun M, He J, Wu C.-Y, Kelsall B. Cholera toxin suppresses interleukin (IL)-12 production und IL-12 receptor β1 and β2 chain expression. J Exp Med 1999; 189:541-52.
49. Schwarze J, Hamelmann E, Cieslewicz G, et al. Local treatment with IL-12 is an effective inhibitor of airway hyperresponsiveness and lung eosinophilia after airway challenge in sensitized mice. J Allergy Clin Immunol 1998; 102:86-93.
50. Leonard JP, Sherman ML, Fisher DL, et al. Effects of single-dose interleukin-12 exposure on interleukin-12 associated toxicity and interferon-gamma production. Blood 1997; 90:2541-8.